Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010

被引:134
作者
Aga, Anna-Birgitte [1 ]
Lie, Elisabeth [1 ]
Uhlig, Till [1 ]
Olsen, Inge Christoffer [1 ]
Wierod, Ada [2 ]
Kalstad, Synove [3 ]
Rodevand, Erik [4 ]
Mikkelsen, Knut [5 ]
Kvien, Tore K. [1 ]
Haavardsholm, Espen A. [1 ]
机构
[1] Diakonhjemmet Hosp, Dept Rheumatol, N-0319 Oslo, Norway
[2] Vestre Viken Drammen Hosp, Dept Rheumatol, Drammen, Norway
[3] Univ Hosp Northern Norway, Dept Rheumatol, Tromso, Norway
[4] St Olavs Hosp, Dept Rheumatol, Trondheim, Norway
[5] Lillehammer Hosp Rheumat Dis, Lillehammer, Norway
关键词
MODIFYING ANTIRHEUMATIC DRUGS; EULAR RECOMMENDATIONS; TREATMENT STRATEGY; CLINICAL-PRACTICE; AMERICAN-COLLEGE; TIGHT CONTROL; COHORTS; THERAPY; METHOTREXATE; MANAGEMENT;
D O I
10.1136/annrheumdis-2013-204020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Methods Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with disease-modifying antirheumatic drugs (DMARDs) were consecutively included and followed longitudinally. Time trend analyses were performed in methotrexate (MTX)-naive RA patients starting MTX monotherapy (MTX mono) and biologic DMARD (bDMARD)-naive RA patients starting tumour necrosis factor inhibitors+MTX (TNFi+MTX). Results A total of 2573 patients were included in the analyses: MTX mono n=1866 (69.9% female, 62.0% RF+, mean (SD) age 56.0 (13.7) years, median (25-75 percentile) time from diagnosis 0.2 (0.01-2.8) years); TNFi+MTX n=707 (70.3% female, 75.0% RF+, mean (SD) age 52.1 (13.2) years, median (25-75 percentile) time from diagnosis 5.7 (2.0-13.7) years). Significant time trends towards lower baseline disease activity score 28 (DAS28) as well as other disease activity measures were found in both groups (DAS28 from 5.17 to 4.75 in MTX mono and from 5.88 to 4.64 in TNFi+MTX), and disease duration became shorter. Six-month DAS28 remission rates increased significantly over the years (from 17.8 to 37.6 in MTX mono and from 16.9 to 46.3 in TNFi+MTX). Conclusions During the last decade, baseline RA disease activity level at the time of starting MTX as well as TNFi+MTX decreased from high to moderate. A more than twofold increase in 6-month remission rates was observed in both groups. Our findings indicate that clinicians have implemented modern, more aggressive treatment strategies, which hopefully will lead to better long-term disease outcomes.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 48 条
[1]   The definition and measurement of disease modification in inflammatory rheumatic diseases [J].
Aletaha, D ;
Smolen, JS .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2006, 32 (01) :9-+
[2]   Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].
Aletaha, D ;
Ward, MM ;
Machold, KP ;
Nell, VPK ;
Stamm, T ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636
[3]   Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH) [J].
Alves, Celina ;
Luime, Jolanda Jacoba ;
van Zeben, Derkjen ;
Huisman, Anne-Margriet ;
Weel, Angelique Elisabeth Adriana Maria ;
Barendregt, Pieternella Johanna ;
Hazes, Johanna Maria Wilhelmina .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (09) :1645-1647
[4]  
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[5]  
2-9
[6]  
[Anonymous], 2007, COCHRANE DATABASE SY
[7]   Disease control with glucocorticoid therapy in rheumatoid arthritis [J].
Bijlsma, Johannes W. J. .
RHEUMATOLOGY, 2012, 51 :iv9-iv13
[8]   The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[9]   Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years - Results from a large observational inception study [J].
Bukhari, MAS ;
Wiles, NJ ;
Lunt, M ;
Harrison, BJ ;
Scott, DGI ;
Symmons, DPM ;
Silman, AJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :46-53
[10]  
de Jong PH, 2012, ANN RHEUM DIS